VanEck Biotech ETF

Quinn Emanuel Fined $3M and Mandated Training for Misleading Court in Natera Case

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research

SBIO

Agilent Technologies has partnered with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to enhance lipid-conjugated oligonucleotide research. This two-year collaboration aims to develop new delivery platforms for oligonucleotides, expanding therapeutic applications beyond liver tissues. The partnership combines NATi's expertise with Agilent's advanced analytical technologies, supporting the growth of the oligo therapeutics market, projected to reach $18 billion by 2030. The agreement also includes training and access to Agilent's Global Solution Development Center in Singapore.

PR Newswire

Agilent Tech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

PHAR

ARKG

LABU

Pharming Group N.V. reported Q1 2026 revenue of $72.4 million, an 8% decline, primarily due to RUCONEST. However, full-year guidance remains intact at $405-$425 million. Joenja showed strong growth with a 34% revenue increase to $14.1 million. The company maintains positive cash flow and a solid balance sheet with $171.8 million in cash. Despite short-term pressures on RUCONEST, management is optimistic about recovery in 2026, supported by a robust pipeline and regulatory advancements for Joenja.

Tip Ranks

Pharming Group NV

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Health Care Select Sector SPDR

iShares US Pharma

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Pharming Group Balances Near-Term Strain With Joenja Growth

BIIB

BioArctic reported a Q1 operating profit of SEK 210.8 million, down from SEK 1.08 billion a year prior. Net revenues fell to SEK 437.6 million from SEK 1.29 billion. Cash flow from operations turned negative at SEK 166 million, while cash and equivalents rose to SEK 2.03 billion. Leqembi sales surpassed EUR 500 million, triggering a EUR 20 million milestone. The FDA extended the review of Leqembi treatment by three months, with a new PDUFA date of Aug. 24, 2026.

PUBT

Biogen

Eisai Co., Ltd.

BioArctic Q1 operating profit drops to SEK 210.8 million; net revenues fall to SEK 437.6 million

ARDX

Ardelyx Inc reported a 38% year-over-year revenue growth in Q1 2026, reaching $93.4 million, driven by strong demand for Ibsrela, which generated $70.1 million. Despite rising operating expenses and competitive pressures, the company reaffirmed its 2026 revenue guidance of $520 million to $550 million. Ardelyx is advancing its pipeline, including the EXCEL Phase 3 trial for Ibsrela, while managing increased costs and cash flow risks. The net loss narrowed to $37.6 million, and the company ended the quarter with $238.1 million in cash.

Ardelyx

SLR Investment

Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs

KPTI

Karyopharm Therapeutics (KPTI) reported Q1 earnings, highlighting strong Phase III data from the SENTRY trial, which showed significant spleen volume reduction and overall survival benefits. Despite a 17% revenue increase to $35.1 million, the company faces competitive pressures and a limited cash runway, with $91.2 million on hand. Management remains optimistic about potential market opportunities in myelofibrosis and endometrial cancer, while acknowledging challenges from new competitors affecting XPOVIO sales.

Karyopharm Therap

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

ROIV

Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average target increased from $35.71, with estimates ranging from $29.5 to $41 per share. The consensus rating remains 'Buy' from 13 analysts, including 12 Buys and 1 Hold.

TradingView

Roivant Sciences

Factset Research

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside

ILMN

Illumina's Q1 earnings call revealed a positive outlook with a revenue of $1.09 billion, exceeding guidance. The company reported strong demand for NovaSeq X and raised its 2026 revenue forecast. Despite challenges in research spending and inflation, Illumina's gross margin improved to 68.2%, and EPS rose to $1.15. The firm also announced a $1.5 billion buyback program and highlighted ongoing product innovations. However, research consumables faced declines, and supply constraints impacted NovaSeq X placements.

Illumina

SOMALOGIC INC

Illumina Earnings Call Signals Confident Clinical Pivot

IMNN

Imunon, Inc. held its Q1 earnings call, highlighting clinical advancements with IMNN-001, which shows promising survival data. However, management expressed concerns over rising cash burn and capital market challenges. The pivotal OVATION III trial is underway, with a focus on minimizing shareholder dilution through strategic financing. Despite strong investigator interest, the lengthy timeline for data and regulatory submission poses risks for investors. The company aims to present detailed efficacy data at an upcoming R&D Day in 2026.

Imunon

Imunon Earnings Call Balances Breakthroughs and Cash Strain

RNXT

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

RenovoRx

SPDR S&P Health Equip

iShares US Medical Devices

RenovoRx Earnings Call Signals Commercial Inflection

CBUS

Cibus, Inc. reported its Q1 earnings, raising $37 million to extend its cash runway to late Q1 2027. The company noted improved cost control, with operating expenses down nearly $8 million, but acknowledged ongoing financial risks and uncertainty in revenue generation. Key developments include progress in its rice program in LATAM and advancements in sustainable ingredients. However, the U.S. rice launch has been delayed to 2029, and profitability remains distant with a net loss of $21.2 million.

Cibus

Cibus Earnings Call: Cash Extended, Execution Critical

510660

Antengene Corporation has appointed Dr. Bing Hou as Chief Scientific Officer to enhance its R&D strategy and advance its next-generation therapeutic pipeline. Dr. Hou, who has been with Antengene since 2019, will lead efforts in Drug Discovery and Translational Medicine. His leadership is expected to strengthen the company's proprietary platforms, including the AnTenGager® T-cell engager platform, and support the development of innovative therapies for autoimmune diseases and cancers.

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

ANTENGENE-B

UCB S.A.

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

VanEck Biotech ETF(BBH.US)